RedHill Biopharma (RDHL) Tops Q4 EPS Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/22/2026
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
- SpaceX, Tesla shares rise after Musk says committees exploring possible merger
- Brent falls as Iran's president discusses mediation with Pakistani army chief
- Abbott plans to spin off its nutrition unit as a standalone public company
- Alphabet shares drop ahead of earnings next week
- Nasdaq leads Wall Street gains as SpaceX, Super Micro boost AI sentiment
- Crude Inventory Fell 3.06 Million Barrels Last Week - EIA
- US orders diplomats to depart Saudi Arabia amid Houthi strikes
RedHill Biopharma (RDHL) Will Present Two BEKINDA Posters at ASCPT Meeting
March 2, 2015 7:08 AM ESTRedHill Biopharma (Nasdaq: RDHL) reported the presentation of two posters at the American Society for Clinical Pharmacology and Therapeutics (ASCPT) 2015 Annual Meeting, to be held between March 3-7, 2015 in New Orleans. The posters describe two previously reported comparative bioavailability studies for BEKINDA (RHB-102), a proprietary, extended-release, once-daily oral pill formulation of the antiemetic drug ondansetron. RedHill is developing BEKINDA for the indications of gastroenteritis and gastritis as well as chemotherapy and radiotherapy-induced nausea and vomiting. The posters will be presented at the ASCPT meeting by the Canadian Contract Research Organization (CRO) who conducted the... More



